Invasive infections with methicillin-resistant Staphylococcus aureus (MRSA) have been associated with increased morbidity and mortality. The aim of the present study was to identify independent predictors of early mortality and treatment failure in patients with MRSA bacteraemia. 
Introduction
Invasive infections with methicillin-resistant Staphylococcus aureus (MRSA) have been associated with greater morbidity and mortality than infections with methicillin-susceptible strains as the result of a combination of host-, pathogen-and therapy-related factors [1, 2] . In Austria the proportion of invasive S. aureus isolates resistant to methicillin is low at 5-10% compared with high resistance rates of 25-50% in southern Europe and 43.2% in the USA [3, 4] . Standard practice in Austria, therefore, does not normally include MRSA antimicrobials in the empirical treatment of critically ill patients.
A number of therapy-unrelated parameters associated with poor clinical outcome have been identified: these include higher patient age, underlying comorbidities such as liver cirrhosis, the site of MRSA infection and the need for early intensive care unit admission [5, 6] . Nevertheless, modified MRSA-specific treatments may improve clinical outcomes. In the past decade, the glycopeptide vancomycin was the antimicrobial of choice for serious MRSA infections such as bacteraemia, endocarditis, pneumonia and osteomyelitis. Reduced susceptibility to glycopeptides is an emerging problem however, and even borderline-high vancomycin MIC of 2 mg/L and low vancomycin trough levels are associated with MRSA treatment failure [7] [8] [9] . As alternatives to vancomycin, newer MRSA-active antibiotics such as the oxazolidinone linezolid, the glycylcycline tigecycline and the cyclic lipopeptide daptomycin have been introduced into clinical practice [10] .
The aim of the present study in patients with MRSA bacteraemia was to determine clinical and microbiological outcomes and to identify independent predictors of treatment failure in a region with low MRSA prevalence.
Patients and Methods

Study design and study population
This retrospective cohort study took place in the University Hospital of Vienna, Austria, a 2141-bed central hospital with a large transplant centre for solid organ transplantation, a haematology-oncology unit that includes a bone marrow transplant unit, and a large intensive care, emergency medicine and surgery unit. After approval by the local ethics committee in 2012 (No. 1469/2012), we screened retrospectively for adult patients with MRSA bacteraemia hospitalized in the University Hospital between January 2000 and September 2011. Only the first episode of MRSA bacteraemia in each patient was included. Patients were excluded if their medical records or microbiological culture for MRSA were not available.
Demographic characteristics obtained from patients' medical records included age, sex, recent major surgery, underlying diseases, comorbidities, source of MRSA bacteraemia (e.g. central venous catheter-related, skin or soft tissue infection, pneumonia, mediastinitis, peritonitis, infective endocarditis), antimicrobial treatment data (type, number of antimicrobials), additional surgical intervention, admittance to intensive care unit, and response to treatment (clinical and microbiological response). Treatment failure was defined as any of the following: 28-day mortality, persistent MRSA bacteraemia lasting ! 7 days or persistent signs and symptoms of infection at the end of antimicrobial therapy. Death was considered to be related to MRSA bacteraemia if one of the following three criteria was present: MRSA-positive blood cultures at the time of death, death occurring before resolution of the signs and symptoms of MRSA bacteraemia, or autopsy finding indicated MRSA infection as a cause of death.
Wherever available from laboratory data, initial vancomycin or teicoplanin trough levels at steady state (immediately before the fourth dose) were evaluated for each patient who received glycopeptides intravenously, because low glycopeptide trough levels might be an important risk factor for treatment failure [11] .
Patients' long-term outcomes (survival or death) 1 year after MRSA bacteraemia were obtained from medical records or from the local central bureau of statistics in Vienna.
Microbiological data
During the study period, relevant MRSA isolates were cryopreserved for later antimicrobial susceptibility testing. The first MRSA organism isolated from the patient's bloodstream was used for microbiological assessment. To determine in vitro susceptibility, MIC of vancomycin, linezolid, tigecycline and fosfomycin were measured in duplicate for each MRSA bloodstream isolate using a broth microdilution method with freshly prepared cation-adjusted M€ uller-Hinton broth and an inoculum of 5 9 10 5 CFU/mL, according to the guidelines of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [12] . According to EUCAST clinical breakpoints isolates were classified as resistant as follows: MIC for vancomycin >2 mg/L, linezolid >4 mg/L, tigecycline >0.5 mg/L and fosfomycin >32 mg/L [13] . Reduced susceptibility of vancomycin was defined as an MIC of 2 mg/L as previously described [8, 9] .
Statistical analysis
To interpret in vitro susceptibility results, the MIC 50 
Results
Characterization of the study patients
A total of 132 patients with MRSA bacteraemia were screened ( Fig. 1 ). Eight patients were non-evaluable, leaving 124 patients (98 men, 26 women) in the final analysis. The median age of patients was 64.5 years (range 18-96 years). Seventy (56.5%) patients had undergone recent major surgery. Median length of hospital stay was 37 days (range 1-203 days); intensive care unit admission was required in 46 (37.1%) patients. Fifty (40.3%) patients died during hospitalization. The underlying diseases included malignant haematological and solid organ neoplasms (n = 36), end-stage kidney disease (n = 19), solid organ transplantation (n = 14), alcoholic liver cirrhosis (n = 14), severe peripheral vascular disease (n = 11), major bleeding (n = 9), polytrauma (n = 7), burn (n = 5), inflammatory bowel disease (n = 3), paraplegia (n = 2), vasculitis (n = 2), pancreatitis (n = 1) and combined human immunodeficiency virus/hepatitis B virus/hepatitis C virus infection (n = 1). Common comorbidities were diabetes mellitus (n = 27), coronary artery disease (n = 23) and chronic obstructive pulmonary disease (n = 17). cases, vancomycin combination therapy with either an aminoglycoside or fosfomycin in 15 cases, teicoplanin monotherapy in 23 cases, and teicoplanin combination therapy with either an aminoglycoside, fosfomycin or linezolid in five cases. Vancomycin trough levels at steady state varied greatly between patients, with a median of 10 mg/L and total range 2.6-45.8 mg/L. Only 14 (22.6%) patients had sufficiently high trough levels of 15-20 mg/L. Median teicoplanin trough levels at steady state were 39 mg/L, range 13.2-147 mg/L. Linezolid and tigecycline were prescribed as initial treatment in seven and two patients, respectively. Daptomycin was used in combination with fosfomycin in a single patient. Fosfomycin, aminoglycosides or rifampicin were administered as combination partners in 15, 16 and two patients, respectively. Fusidic acid, cotrimoxazole and clindamycin were used in a total of seven patients. Twenty-eight (22.6%) patients underwent additional surgical intervention for source control. Six patients received no MRSA-active treatment and all died. Antimicrobial combination therapy was used in 30 (24.2%) patients. Persistent bacteraemia ! 7 days was less common in patients with combination therapy (3/25 (12%) patients versus 27/99 (27.3%) patients), but no statistical significance was reached (p 0.13). (Table 2 ). All isolates were susceptible to linezolid and tigecycline and five (4%) were resistant to fosfomycin. Resistance to vancomycin (MIC >2 mg/L) was detected in 0.8%, reduced susceptibility to vancomycin (MIC = 2 mg/L) was found in 27.4% of MRSA bloodstream isolates. 
Clinical and microbiological treatment failure
The 28-day mortality in the study population was 30.6% and death could be related to MRSA bacteraemia in 23.4%. The crude mortality rate increased to 41.9% in the first half-year after MRSA bacteraemia and reached 45.2% after the first year (Fig. 1) . Increasing age, solid organ transplantation, pneumonia and failure to use an antimicrobial active against MRSA showed significant influence on early mortality within the first 28 days in the univariate Cox regression analyses (p <0.1). Looking at a multivariate model including those four risk factors, only three parameters remained statistically significant: higher patient age (aHR 1.03, 95% CI 1.01-1.06, p 0.006), pneumonia as site of infection (aHR 3.86, 95% CI 1.83-8.12, p <0.001) and failure to use an MRSA-active antimicrobial substance (aHR 8.75, 95% CI 3.50-21.88, p <0.001). Differences between the Kaplan-Meier survival curves of patients with and without pneumonia after a follow up of 1 year are shown in Fig. 2 . Among patients with MRSA bacteraemia, 64.7% of those with pneumonia and 42.1% of those without pneumonia had died at the end of the followup period of 1 year.
Twenty-five (20.2%) patients developed persistent MRSA bacteraemia ! 7 days. Two positive predictors for microbiological eradication failure (p <0.1) were identified in the univariate analyses: endocarditis and vancomycin monotherapy. As negative predictors (p <0.1), persistent bacteraemia was detected significantly less often in patients with central venous catheter-related bacteraemia and in patients with high [15] . As expected, the most important aspect of MRSA treatment in our study was timely identification of methicillin resistance. MRSA is a rare bloodstream pathogen in Austrian patients [16] and all patients who did not receive MRSA-active treatment died from fulminant sepsis <72 h after the blood culture was taken. In accordance with previous studies, increasing age was an independent risk factor of early mortality [5, 7, 14, 15] . In addition, we identified pneumonia as independent positive predictor of 28-day mortality in our study patients.
Vancomycin, which has been available for over 50 years [17] , was still used in our institution most frequently, in 50.8% patients with MRSA bacteraemia. However, at least in univariate analysis, vancomycin monotherapy was associated with persistent MRSA bacteraemia ! 7 days. Most authors agree that vancomycin has limitations such as low tissue penetration, nephrotoxicity and increasing rates of treatment failure in invasive MRSA infections [8] . During the observation period, in vitro susceptibility testing against MRSA in our institution was routinely performed using agar diffusion tests (standard Etest on M€ uller-Hinton agar or Etest detection of glycopeptide resistance using a vancomycin-teicoplanin double-sided gradient test). According to Performance Standards for Antimicrobial Susceptibility Testing/CLSI or EUCAST clinical breakpoints, all MRSA isolates were originally reported as susceptible to vancomycin (data not shown). However, low level resistance to vancomycin continues to evolve [7, 18] . We therefore retrospectively assessed the in vitro susceptibility of MRSA blood isolates using the broth microdilution reference method in addition and detected reduced susceptibility to vancomycin, defined as MIC of 2 mg/L, in 27.4% of MRSA isolates. One single strain had a vancomycin MIC of 4 mg/L on re-testing, but had been initially reported as susceptible by the standard Etest method in 2002 because of the higher vancomycin breakpoint of 4 mg/L in use at that time. Previously, Etest MIC of 1.5 mg/L or ! 2 mg/L appeared to be an important boundary indicating imminent clinical failure [8] or increased mortality in bloodstream infections, retrospectively [9] . However, similar to the finding by Rojas et al. [19] , we detected no relationship between vancomycin MIC ! 2 mg/L determined in the broth microdilution method and clinical or microbiological eradication failure. Nevertheless, we found a significant association between vancomycin MIC and glycopeptide preteatment as previously described by Lodise et al. [20] .
Furthermore, the site of MRSA infection and source control are crucial for clinical outcome. In the present study the presence of endocarditis and the absence of high vancomycin trough levels at steady state were significantly associated with clinical and microbiological eradication failure. Although vancomycin trough levels of 15-20 mg/L are recommended worldwide to attain a vancomycin area under the curve/MIC ratio ! 400 [21] , only 22.6% of our patients receiving vancomycin reached the targeted drug levels, possibly reflecting low-level recommendations for a maximum trough level of 10.15 mg/L in 2000 and 14.5 mg/L in 2011 by the Department of Laboratory Medicine at our institution.
Effective alternatives to vancomycin for treatment of invasive MRSA infections are limited. The other glycopeptide used as the second most common MRSA-active agent in the present study was teicoplanin, for which sufficient trough levels ! 20 mg/L were achieved in 85.7% of patients. However, for patients infected with isolates with reduced glycopeptide susceptibility, another class of antimicrobial substances might be more appropriate [22] . Although all the MRSA isolates tested were susceptible to linezolid and tigecycline, only a small number of patients received one of these agents. A limitation of the study was that we did not determine in vitro susceptibility to daptomycin retrospectively. However, in our institution daptomycin was only used as the initial MRSA regimen in combination with fosfomycin in a single patient.
In conclusion, failure of clinical and microbiological eradication was associated with endocarditis and low vancomycin trough levels, whereas vancomycin MIC values ! 2 mg/L had no impact on treatment failure. There is therefore a strong need for early diagnosis of MRSA bacteraemia, with identification of the site of infection, optimization of vancomycin dosing, appropriate use of vancomycin alternatives or combination therapy, and optimal case management including source control. 
